Keyphrases
Adjusted Relative Risk
13%
AIDS/HIV
45%
Antiretroviral Therapy
33%
Area under the Curve
12%
At Discharge
16%
Brain Abscess
41%
CD4 T Cells
13%
Cerebrospinal Fluid
15%
Clinical Features
25%
Combined Antiretroviral Therapy (cART)
12%
Community-acquired Bacterial Meningitis
19%
Confidence Interval
36%
Denmark
100%
Encephalitis
15%
Feature Factors
19%
Glasgow Outcome Scale
28%
Growth Factors
23%
Growth Hormone
33%
Growth Hormone Treatment
32%
Headache
17%
Herpes Simplex Virus 2 (HSV-2)
25%
Highly Active Antiretroviral Therapy (HAART)
21%
HIV Infection
23%
HIV Patients
52%
HIV-associated Lipodystrophy Syndrome
13%
Infected Patients
39%
Infectious Diseases
22%
Insulin Resistance
24%
Insulin-like
23%
Leukocyte Count
15%
Lipodystrophy
39%
Lumbar Puncture
13%
Lyme Neuroborreliosis
21%
Meningitis
59%
National Cohort Study
86%
Observational Cohort Study
19%
Oral Cavity Bacteria
13%
Prognostic Factors
23%
Prospective Cohort Study
49%
Protease Inhibitors
16%
Randomized Placebo-controlled Trial
14%
Recombinant Human Growth Hormone (r-hGH)
35%
Recombinant Human Growth Hormone Therapy
19%
Relative Risk
24%
Risk Factors
25%
Risk Prognosis
19%
Unfavorable Outcome
46%
Varicella Zoster Virus
29%
Viral
13%
Viral Meningitis
21%
Medicine and Dentistry
Antibiotics
11%
Antiretroviral Therapy
39%
Bacterial Meningitis
23%
Brain Abscess
41%
Central Nervous System Infection
14%
Cerebrospinal Fluid
14%
Clinical Feature
24%
Cohort Analysis
73%
Cohort Effect
13%
Cohort Study
9%
Diabetic Ketoacidosis
9%
Enterovirus
12%
Epileptic Seizure
11%
Glasgow Outcome Scale
23%
Growth Hormone
29%
Headache
17%
Herpes Simplex Virus 2
21%
Herpes Zoster Encephalitis
9%
Highly Active Antiretroviral Therapy
13%
HIV-associated Lipodystrophy
10%
Hormone Sensitivity
9%
Human Growth Hormone
23%
Human Immunodeficiency Virus
49%
Human Immunodeficiency Virus Infection
19%
Immunocompromised Patient
18%
Infection
38%
Insulin Resistance
14%
Intra-Abdominal Fat
9%
Leukocyte
14%
Lipodystrophy
19%
Lumbar Puncture
13%
Lyme Neuroborreliosis
21%
Magnetic Resonance Imaging
11%
Meningitis
57%
Metabolic Syndrome
9%
Neck
10%
Neurosyphilis
11%
Oral Cavity
13%
Placebo
10%
Prevalence
17%
Prognostic Factor
23%
Prospective Cohort Study
42%
Proteinase Inhibitor
17%
Pulmonary Arteriovenous Fistula
9%
Radiculitis
11%
Streptococcus Pneumoniae
11%
Symptom
20%
Target Tissue
9%
Varicella Zoster Virus
18%
Virus Meningitis
21%
Pharmacology, Toxicology and Pharmaceutical Science
Antibiotics
10%
Bacterial Meningitis
22%
Binding Protein
11%
Brain Abscess
21%
Central Nervous System Infection
11%
Clinical Feature
22%
Cohort Study
61%
Dexamethasone
9%
Diabetic Ketoacidosis
9%
Endocrine Therapy
38%
Epidemiology
9%
Glasgow Outcome Scale
19%
Growth Hormone
64%
Growth Hormone Binding Protein
10%
Headache
13%
Herpes Simplex Virus 2
20%
Herpes Zoster Encephalitis
9%
Herpes Zoster Oticus
9%
HIV
68%
HIV Associated Lipodystrophy
15%
Human Growth Hormone
47%
Human Immunodeficiency Virus 1
9%
Human Immunodeficiency Virus Infection
20%
Immunocompromised Patient
20%
Infection
26%
Infectious Agent
10%
Inflammation
9%
Insulin Resistance
14%
Lipodystrophy
25%
Lyme Neuroborreliosis
21%
Meningitis
46%
Metabolic Syndrome X
9%
Perception Deafness
9%
Placebo
21%
Placebo-Controlled Study
19%
Prevalence
9%
Prospective Cohort Study
21%
Proteinase
9%
Proteinase Inhibitor
17%
RNA Directed DNA Polymerase Inhibitor
7%
Somatomedin
9%
Somatomedin Binding Protein
9%
Somatomedin Binding Protein 3
9%
Somatomedin C
15%
Streptococcus Group A
9%
Symptom
13%
T Lymphocyte Receptor
11%
Tooth Infection
7%
Varicella Zoster Virus
17%
Virus Meningitis
31%
